BioArctic Advances Exidavnemab Study Following Positive Safety Review

BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an update.

BioArctic AB announced the initiation of the next cohorts in its Phase 2a study of exidavnemab following a positive interim safety review. Exidavnemab, a monoclonal antibody targeting pathological alpha-synuclein aggregates, is being developed as a treatment for Parkinson’s disease and Multiple System Atrophy (MSA). The study’s progression to higher doses marks a significant step in addressing the unmet medical need for disease-modifying treatments in synucleinopathies. Exidavnemab has received orphan drug designation in the US and a positive opinion in the EU for MSA treatment, highlighting its potential impact on the company’s operations and industry positioning.

More about BioArctic AB Class B

BioArctic AB is a Swedish research-based biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. The company is known for its work on Leqembi®, a drug proven to slow the progression of Alzheimer’s disease. BioArctic’s research portfolio includes projects on Alzheimer’s, Parkinson’s, ALS, and enzyme deficiency diseases, utilizing its proprietary BrainTransporter™ technology. The company’s B share is listed on Nasdaq Stockholm Large Cap.

Average Trading Volume: 305,970

Current Market Cap: SEK17.94B

See more insights into BIOA.B stock on TipRanks’ Stock Analysis page.